-1 	|BT| (NP (NP (NNP Folate) (NN transport) (NN gene) (NN inactivation) (NN mouse) (NN increase) (NN sensitivity) (NN colon) (NN carcinogenesis))) |ET| |BS|11:B01.050.150.900.649.865.635.505.500 33:C04.697.098 42:G05.355.315.203.374 46:A03.556.124.526.356 224:D03.438.733.631.400 947:G03.495.166|ES| 9:1 19:1 40:1 52:1 113:1 207:1 607:1 1314:1 3318:1 3488:1
-1 	|BT| (S (PP (IN For) (NP (NN example))) (, ,) (NP (NP (NN gene) (VBN involved) (NN inflammation) (NN matrix) (NN protease) (NN cell) (NN cycle) (NN regulator) (NN gene)) (, ,) (NP (NN cyclin) (NN D2)) (, ,)) (ADVP (RB highly)) (VP (VBN expressed) (NP (NN colon) (NN cancer)))) |ET| |BS|6:G05.360.340.024.340 525:C23.550.470 995:D12.644.360.262.150.200 996:G05.360.340.024.340.220 997:D08.811.277.656.300 998:D08.811.277.656|ES| 2:1 6:1 9:1 18:1 19:1 94:1 113:1 235:1 601:1 626:1 743:1 774:1 3064:1 3489:1 3490:1 3491:1 3492:1 3493:1
-1 	|BT| (S (NP (NN Forkhead) (NN box) (NN transcription) (NN factor) (NN FOXO3a)) (VP (VBZ suppresses) (NP (JJ estrogen-dependent) (NN breast) (NN cancer) (NN cell) (NN proliferation) (NN tumorigenesis)))) |ET| |BS|32:C04.697.098.500 33:C04.697.098 166:D12.776.930 183:G04.299.233.750 889:D27.505.696.399.472.277|ES| 18:1 19:1 23:1 78:1 94:1 185:1 299:1 487:1 686:1 1918:1 3361:1 3363:1 3494:1
-1 	|BT| (S (NP (NP (NNP Gefitinib)) (, ,) (NP (NN EGFR) (NN inhibitor)) (, ,)) (VP (VBZ prevents) (NP (JJ hepatocellular) (NN carcinoma) (NN development) (NN rat) (NN liver) (NN cirrhosis)))) |ET| |BS|104:C04.557.470.200.025.255 242:A03.620 245:B01.050.150.900.649.865.635.505.700 246:B01.050.150.900.649.865.635.505.700 357:C06.552.630 662:C23.550.355|ES| 2:1 19:1 35:1 187:1 303:1 304:1 380:1 836:1 849:1 1199:1 2718:1 3024:1
-1 	|BT| (S (NP (NNS Genes)) (VP (VBD expressed) (NP (NP (NN PB) (CD two) (NNS conazoles)) (RRC (ADVP (RB also)) (NP (VBN compared) (NP (NN gene) (VBN associated) (JJ human) (JJ hepatocellular) (NN cancer))))))) |ET| |BS|6:G05.360.340.024.340 55:B01.050.150.900.649.801.400.112.400.400|ES| 5:1 6:1 9:1 18:1 19:1 36:1 50:1 169:1 303:1 933:1 3495:1 3496:1 3497:1
-1 	|BT| (SINV (NP (NP (NNP Geraniol)) (, ,) (NP (NN component) (NN plant) (JJ essential) (NN oil)) (, ,)) (VP (VBZ modulates) (NP (NN DNA) (NN synthesis))) (VP (VBZ potentiates) (NP (NN 5-fluorouracil) (NN efficacy) (JJ human) (NN colon) (NN tumor) (NN xenograft)))) |ET| |BS|51:C04.588.274.476.411.307.180 55:B01.050.150.900.649.801.400.112.400.400 78:G02.111.087.222 92:E04.936.764 93:A01.941.875 560:D03.383.742.698.875.404 999:D10.627.675 1000:A18|ES| 2:1 7:1 19:1 36:1 113:1 265:1 606:1 666:1 1021:1 1098:1 1776:1 2304:1 2307:1 2499:1 2614:1 3436:1 3498:1
-1 	|BT| (S (NP (NN Glycine) (NN soya) (NN diet)) (ADVP (RB synergistically)) (VP (VBZ enhances) (SBAR (S (NP (JJ suppressive) (NN effect) (NN tamoxifen)) (VP (VBZ inhibits) (NP (NP (JJ tamoxifen-promoted) (NN hepatocarcinogenesis)) (JJ 7,12-dimethylbenz) (PRN (-LRB- -LSB-) (NP (NN alpha)) (-RRB- -RSB-)) (JJ anthracene-induced) (NN rat) (JJ mammary) (NN tumor) (NN model))))))) |ET| |BS|122:C14.280.383 245:B01.050.150.900.649.865.635.505.700 246:B01.050.150.900.649.865.635.505.700 408:C04.588.531 595:G07.203.650.240 596:E02.642.249 640:D02.455.426.559.389.150.700.900 1001:B01.650.940.800.575.100.401.750 1002:C04.588.180 1003:D12.125.481|ES| 7:1 19:1 72:1 75:1 615:1 849:1 900:1 1356:1 1373:1 1378:1 1836:1 1974:1 2191:1 2248:1 2371:1 3349:1 3499:1 3500:1 3501:1 3502:1 3503:1
-1 	|BT| (NP (NP (JJ Hepatoprotective) (NN effect) (NN tamoxifen) (NN steatosis) (JJ non-alcoholic) (NN steatohepatitis) (NN mouse) (NN model))) |ET| |BS|11:B01.050.150.900.649.865.635.505.500 508:C06.552.241 509:C06.552.241.519 640:D02.455.426.559.389.150.700.900|ES| 19:1 52:1 72:1 75:1 1791:1 2069:1 2371:1 2678:1 3504:1
-1 	|BT| (S (VP (ADVP (RB Here)) (VBP show) (SBAR (S (NP (NP (JJ ATP-binding) (NN cassette) (NN member) (NN B5)) (PRN (-LRB- -LRB-) (NP (NN ABCB5)) (-RRB- -RRB-))) (VP (VBZ identifies) (NP (NP (JJ therapy-refractory) (NN tumor) (NN cell) (JJ colorectal) (NN cancer) (NN patient)) (PP (VBG following) (NP (NP (NN fluorouracil)) (PRN (-LRB- -LRB-) (NP (NN 5-FU)) (-RRB- -RRB-)))))))) (: -) (S (NP (VBN based) (NN chemoradiation) (NN therapy)) (VP (VBP provide) (NP (NP (NN evidence)) (JJ functional) (NN role) (NN ABCB5) (JJ colorectal) (NN cancer) (NN 5-FU) (NN resistance)))))) |ET| |BS|4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 8:C04 15:F01.829.316.616 50:M01.643 52:E02 59:E02.186.079 333:D01.045 560:D03.383.742.698.875.404 1004:E02.095.147|ES| 7:1 10:1 14:1 17:1 18:1 19:1 31:1 38:1 94:1 120:1 130:1 400:1 415:1 429:1 711:1 769:1 1094:1 1610:1 2308:1 2895:1 2919:1 3505:1 3506:1 3507:1 3508:1 3509:1 3510:1 3511:1
-1 	|BT| (S (ADVP (RB Here)) (, ,) (VP (VBP provide) (NP (NP (NP (NN evidence) (NN periostin) (, ,) (NN protein) (JJ structural) (NN sequence) (NN homology) (JJ TGF-beta-inducible) (NN gene)) (, ,) (NP (NN beta) (NN ig-h3)) (, ,)) (VP (VBN upregulated) (NP (JJ colorectal) (NN cancer) (NN liver) (NN metastasis)))) (, ,) (VP (MD may) (VP (VB play) (NP (NN role)) (S (VP (VBG promoting) (NP (NN growth) (NN tumor)))))))) |ET| |BS|4:C04.588.274.476.411.307 6:G05.360.340.024.340 8:C04 15:F01.829.316.616 45:G07.700.320.249 79:I03.450.642.693 112:D12.776.097.820 113:C04.697.650 242:A03.620 503:D12.644.276.374.687 1005:G02.111.810|ES| 2:1 4:1 7:1 9:1 17:1 18:1 19:1 31:1 38:1 102:1 125:1 238:1 293:1 400:1 491:1 711:1 806:1 836:1 881:1 1972:1 3512:1 3513:1 3514:1 3515:1 3516:1
-1 	|BT| (UCP (ADVP (RB Here)) (, ,) (NP (NP (NN report) (NN identification) (JJ hepatic) (NNS microRNAs)) (SBAR (S (NP (VBN dysregulated) (JJ early) (NN stage) (S (VP (VBG feeding) (NP (NP (NP (NN C57BL/6) (NN mouse) (JJ choline-deficient) (NN amino) (JJ acid-defined)) (-LRB- -LRB-) (JJ CDAA) (-RRB- -RRB-) (NN diet)) (ADJP (VBN known)))))) (VP (VBP promote) (FRAG (NP (NP (JJ nonalcoholic) (NN steatohepatitis)) (PRN (-LRB- -LRB-) (NP (NN NASH)) (-RRB- -RRB-))) (: -) (NP (VBN induced) (NN hepatocarcinogenesis) (CD 84) (NN week)))))))) |ET| |BS|30:Z01.058.290.190.800 31:D08.811.520.224.800 184:D13.150.650.319 374:F01.393.446 509:C06.552.241.519 593:B01.050.050.199.520.520.420 594:D02.033.100.291.211 595:G07.203.650.240 596:E02.642.249 597:D12.125|ES| 2:1 10:1 14:1 19:1 52:1 400:1 409:1 417:1 556:1 679:1 783:1 838:1 900:1 1128:1 1129:1 1259:1 1791:1 1796:1 2188:1 2189:1 2190:1 2191:1 2192:1 2942:1 3065:1 3184:1 3469:1 3517:1 3518:1
-1 	|BT| (S (ADVP (RB Here)) (, ,) (NP (NN report) (NNP MPA)) (ADVP (RB also)) (VP (VBZ induces) (NP (NP (NN differentiation) (JJ androgen-independent) (NN prostate) (NN cancer)) (NP (VBN derived) (NN cell) (NN line) (NN DU145))))) |ET| |BS|74:G04.299.151 94:A11.251.210 852:C04.588.945.440.770.500|ES| 2:1 5:1 18:1 19:1 77:1 94:1 214:1 215:1 264:1 400:1 417:1 1721:1 3423:1 3519:1 3520:1
-1 	|BT| (S (ADVP (RB Herein)) (, ,) (VP (VBD found) (SBAR (IN whereas) (S (VP (VBG sparing) (NP (NP (JJ normal) (NP (JJ human) (NN colon) (JJ mucosal) (JJ epithelial) (NN cell))) (, ,) (NP (NN EPLE))) (VP (ADVP (RB selectively)) (VBD inhibited) (NP (NN proliferation) (NN CRC) (NN cell) (NN line)) (ADVP (RB well)) (NP (JJ primary) (NN tumor) (NN cell)))))))) |ET| |BS|4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 8:C04 41:A11 46:A03.556.124.526.356 55:B01.050.150.900.649.801.400.112.400.400 75:A11.436 122:C14.280.383 183:G04.299.233.750 302:A10.615.550|ES| 2:1 7:1 19:1 36:1 37:1 94:1 113:1 118:1 127:1 245:1 264:1 299:1 344:1 365:1 372:1 428:1 787:1 2489:1 3521:1 3522:1 3523:1
-1 	|BT| (S (ADVP (RB Herein)) (, ,) (VP (VBD investigated) (NP (NP (NP (NN effect) (NN alpha-LA) (NN development) (NN rat)) (JJ pre-neoplastic) (NN lesion)) (VP (VBD generated) (NP (NN model) (NN hepatocarcinogenesis) (, ,) (NN similarity) (JJ histopathological) (NN sequence) (JJ human) (JJ hepatocellular) (NN carcinoma) (NN development) (NN cirrhosis)))))) |ET| |BS|8:C04 14:F01.525 25:G02.111.570.080 26:G02.111.570.080 27:G02.111.570.080 30:Z01.058.290.190.800 31:D08.811.520.224.800 104:C04.557.470.200.025.255 245:B01.050.150.900.649.865.635.505.700 246:B01.050.150.900.649.865.635.505.700 357:C06.552.630 662:C23.550.355 1006:D01.268.558.362.500|ES| 2:1 19:1 35:1 36:1 72:1 73:1 75:1 293:1 303:1 304:1 403:1 428:1 849:1 900:1 1131:1 1199:1 3524:1 3525:1 3526:1 3527:1
-1 	|BT| (S (ADVP (RB Herein)) (, ,) (VP (VBD investigated) (NP (NP (ADJP (FW vitro) (FW vivo)) (JJ anticancer) (NN effect)) (NP (VBN associated) (NN mechanism) (NN wogonin) (JJ human) (NN breast) (NN cancer))))) |ET| |BS|55:B01.050.150.900.649.801.400.112.400.400|ES| 2:1 18:1 19:1 23:1 36:1 75:1 162:1 169:1 216:1 378:1 403:1 428:1 1880:1 2444:1
-1 	|BT| (S (NP (NN Histone) (NN deacetylase) (CD 6) (NN function) (NN tumor) (NN suppressor)) (VP (VBG activating) (NP (NN c-Jun) (JJ NH2-terminal) (JJ kinase-mediated) (NN beclin) (JJ 1-dependent) (JJ autophagic) (NN cell) (NN death) (NN liver) (NN cancer)))) |ET| |BS|206:G05.360.340.024.340.375.249 771:D08.811.913.696.620.682.700.567.374 1007:G04.299.139.399 1008:D08.811.277.087.520|ES| 7:1 18:1 19:1 33:1 94:1 411:1 504:1 700:1 836:1 1686:1 1958:1 2140:1 2708:1 3528:1 3529:1 3530:1 3531:1 3532:1
-1 	|BT| (S (NP (NN Honokiol)) (VP (VP (VBZ activates) (NP (JJ AMP-activated) (NN protein) (NN kinase) (NN breast) (NN cancer) (NN cell)) (PP (IN via) (NP (JJ LKB1-dependent) (NN pathway)))) (VP (VBZ inhibits) (NP (NN breast) (NN carcinogenesis))))) |ET| |BS|10:A01.236 33:C04.697.098 41:A11 122:C14.280.383 1009:D08.811.913.696.620.682.700.085|ES| 4:1 18:1 19:1 23:1 94:1 207:1 301:1 383:1 470:1 596:1 615:1 3533:1 3534:1 3535:1
-1 	|BT| (S (ADVP (RB However)) (, ,) (NP (JJ molecular) (NN mechanism) (NN progesterone) (NN action) (NN breast) (NN cancer)) (ADVP (RB still)) (VP (VBP remain) (ADJP (JJ elusive)))) |ET| |BS|742:G03.787 1010:D04.808.745.745.654.829|ES| 2:1 18:1 19:1 23:1 161:1 162:1 433:1 776:1 777:1 2013:1 2181:1 3536:1
-1 	|BT| (S (NP (NP (JJ Hypoxia-inducible) (NN factor)) (PRN (-LRB- -LRB-) (NP (NNS HIFs)) (-RRB- -RRB-))) (VP (VBP accumulate) (NP (NP (JJ neoplastic) (JJ inflammatory) (NN cell)) (PP (IN within) (NP (NN tumor) (NN microenvironment) (NN impact) (NN progression) (NN variety) (NN disease))) (, ,) (PP (VBG including) (NP (JJ colorectal) (NN cancer)))))) |ET| |BS|4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 8:C04 16:C23.550.291.656 41:A11 1011:C23.888.852.079 1012:G04.366.500|ES| 2:1 7:1 10:1 14:1 17:1 18:1 19:1 48:1 94:1 185:1 561:1 893:1 952:1 998:1 2122:1 2430:1 3537:1 3538:1 3539:1 3540:1 3541:1
-1 	|BT| (NP (NP (NP (JJ Immunohistochemical) (NN analysis) (NN thymidylate) (NN synthase)) (, ,) (NP (NN thymidine) (NN phosphorylase)) (, ,) (NP (NP (NN dihydropyrimidine) (NN dehydrogenase) (JJ rectal) (NN cancer)) (PRN (-LRB- -LRB-) (NP (NN cUICC) (NN II/III)) (-RRB- -RRB-))) (: :)) (NP (NP (NN correlation) (JJ histopathologic) (NN tumor) (NN regression)) (NP (JJ 5-fluorouracil-based) (JJ long-term) (NN neoadjuvant) (NN chemoradiotherapy)))) |ET| |BS|8:C04 59:E02.186.079 333:D01.045 560:D03.383.742.698.875.404 713:D08.811.913.555.500.862 846:F01.393.784 849:G08.686.785.760.769.490.500 869:D08.811.913.400.725.850.500 870:D08.811.682.660.350 1013:E02.186.450|ES| 2:1 7:1 10:1 14:1 18:1 19:1 66:1 104:1 661:1 719:1 1986:1 1989:1 2578:1 2648:1 3002:1 3082:1 3083:1 3084:1 3085:1 3542:1 3543:1 3544:1 3545:1 3546:1 3547:1
-1 	|BT| (S (PP (IN In) (NP (NN conclusion))) (, ,) (NP (NN Folbp1) (NN RFC1)) (ADVP (RB genetically)) (VP (NP (VBN modified) (NN mouse) (NN exhibit) (JJ distinct) (NN change) (NN colonocyte) (NN phenotype)) (ADVP (RB therefore)) (SBAR (S (NP (NN utility) (NN model)) (VP (VBP examine) (NP (NP (NN role)) (JJ folate) (NN homeostasis) (NN colon) (NN cancer) (NN development))))))) |ET| |BS|11:B01.050.150.900.649.865.635.505.500 15:F01.829.316.616 30:Z01.058.290.190.800 31:D08.811.520.224.800 80:G05.695 152:G07.700.345 175:J01.897.280.500.269 224:D03.438.733.631.400|ES| 2:1 18:1 19:1 31:1 35:1 52:1 72:1 113:1 200:1 218:1 236:1 244:1 500:1 587:1 778:1 898:1 960:1 1284:1 2026:1 2194:1 2335:1 3548:1 3549:1 3550:1
-1 	|BT| (S (PP (IN In) (NP (NN conclusion))) (, ,) (VP (VBP result) (VP (VBP indicate) (SBAR (S (NP (JJ insulin-independent) (NN liver) (NN tumor) (NN promotion)) (VP (VBD occurred) (NP (JJ diabetic) (NN mouse)))))))) |ET| |BS|11:B01.050.150.900.649.865.635.505.500 515:C04.588.274.623 637:D06.472.699.587.200.500.625|ES| 2:1 7:1 19:1 52:1 101:1 244:1 553:1 836:1 1284:1 1479:1 2337:1 2964:1 3551:1
-1 	|BT| (S (PP (IN In) (NP (NN contrast))) (, ,) (NP (NP (JJ high) (NN level) (NN sPLA2) (NN expression)) (JJ likely) (VBG contributing) (JJ elevated) (NN level) (JJ arachidonic) (NN acid)) (VP (VBD found) (SBAR (S (NP (NP (JJ colorectal) (NN cancer)) (, ,) (NP (NN conjunction) (JJ elevated) (NN expression) (NN cyclooxygenase-2)) (, ,)) (VP (MD could) (NP (DT another) (NN factor) (NN tumor) (NN formation))))))) |ET| |BS|4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 8:C04 20:G03.495 24:D08.811.600.720.750 491:D27.505.259.500 1014:D10.251.355.255.100.100|ES| 2:1 7:1 17:1 18:1 19:1 37:1 43:1 61:1 115:1 178:1 185:1 244:1 249:1 756:1 908:1 1275:1 1295:1 1328:1 1392:1 3552:1 3553:1 3554:1 3555:1
-1 	|BT| (S (PP (IN In) (NP (NN HepG2) (NN cell))) (, ,) (S (S (NP (NN transfection) (NN RARgamma)) (VP (VBD enhanced))) (, ,) (IN whereas) (S (NP (NN downregulation) (NN RARgamma) (NN expression) (NN siRNA) (NN approach)) (VP (VBD impaired)))) (, ,) (NP (NN effect) (NN RA) (VBG inducing) (NN expression) (NN alpha-fetoprotein) (, ,) (NN protein) (NN marker) (NN hepatocarcinogenesis))) |ET| |BS|85:G02.111.087.225 112:D12.776.097.820 117:D13.150.650.700 158:D23.101 217:E05.393.350.810 748:D12.776.124.790.106.092 1015:A11.251.860.180.432|ES| 2:1 4:1 19:1 75:1 94:1 115:1 244:1 351:1 372:1 385:1 534:1 595:1 746:1 900:1 911:1 1864:1 2003:1 2665:1 3481:1 3556:1 3557:1
-1 	|BT| (S (PP (IN In) (NP (JJ human) (JJ colorectal) (NN cancer))) (, ,) (NP (JJ arachidonic) (NN acid) (NN eicosanoid) (NN level)) (VP (VBD elevated))) |ET| |BS|4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 55:B01.050.150.900.649.801.400.112.400.400 1014:D10.251.355.255.100.100 1016:D10.251.355.255|ES| 2:1 17:1 18:1 19:1 36:1 244:1 249:1 756:1 1275:1 3553:1 3558:1
-1 	|BT| (S (PP (IN In) (NP (JJ current) (NN study))) (, ,) (NP (NN serial) (NN microPET) (NN imaging)) (VP (VBD used) (VP (VB evaluate) (NP (NP (JJ iodine-124-labeled) (NN iodo-azomycin-galactoside)) (PRN (-LRB- -LRB-) (NP (-LRB- -LRB-) (CD 124) (-RRB- -RRB-) (NN I-IAZG)) (-RRB- -RRB-))))) (PRN (-LRB- -LRB-) (NP (JJ 4.2-day) (JJ physical) (NN half-life)) (-RRB- -RRB-)) (S (NP (NN hypoxia) (NN imaging) (NN agent)) (NP (CD 17) (NN MCa) (NN breast) (NN tumor) (CD six) (NN FSaII) (NNS fibrosarcomas)) (VP (VBN implanted) (NP (NN mouse))))) |ET| |BS|11:B01.050.150.900.649.865.635.505.500 30:Z01.058.290.190.800 31:D08.811.520.224.800 225:E05.337 375:Z01.639.100 967:D01.248.497.158.490 1002:C04.588.180 1011:C23.888.852.079 1017:E01.370.350 1018:C04.557.450.565.590.350 1019:A07.231.114.228.550 1020:G01.910.405 1021:E01.370.600 1022:V02.690|ES| 2:1 7:1 10:1 14:1 19:1 23:1 52:1 131:1 175:1 244:1 476:1 728:1 890:1 930:1 1781:1 2474:1 3559:1 3560:1 3561:1 3562:1 3563:1 3564:1 3565:1 3566:1 3567:1 3568:1 3569:1 3570:1 3571:1 3572:1
-1 	|BT| (S (PP (IN In) (NP (JJ present) (NN study))) (, ,) (VP (VBD sought) (VP (VB examine) (SBAR (S (NP (NN effectiveness) (NN honokiol) (VBG inhibiting) (NP (NN migration) (NN invasion) (NN breast) (NN cancer) (NN cell))) (VP (VBP elucidate) (S (VP (VBG underlying) (NP (JJ molecular) (NN mechanism)))))))))) |ET| |BS|30:Z01.058.290.190.800 31:D08.811.520.224.800 41:A11 122:C14.280.383|ES| 2:1 18:1 19:1 23:1 94:1 131:1 161:1 162:1 219:1 244:1 435:1 514:1 620:1 880:1 960:1 1307:1 1697:1 3573:1 3574:1
-1 	|BT| (S (PP (IN In) (NP (NN study))) (, ,) (VP (VBD determined) (NP (NP (JJ combined) (NN effect) (NN celecoxib)) (, ,) (NP (NN COX-2) (NN inhibitor)) (, ,)) (PP (IN along) (NP (NP (NP (NN exisulind)) (PRN (-LRB- -LRB-) (NP (NN sulindac) (NN sulfone/Aptosyn)) (-RRB- -RRB-))) (JJ low) (NNS dos) (NN prostate) (NN cancer))))) |ET| |BS|349:D27.505.519.389.310.500 684:D02.065.884.247|ES| 2:1 10:1 14:1 18:1 19:1 75:1 76:1 77:1 131:1 164:1 244:1 380:1 531:1 869:1 1582:1 2653:1 2666:1 2807:1 3575:1 3576:1
-1 	|BT| (S (PP (IN In) (NP (NN study))) (, ,) (NP (NP (VBN investigated) (NN role) (NN progastrin)) (VP (VBG regulating) (NP (NNP CSC) (NN phenotype)))) (VP (VBD advanced) (NP (JJ colorectal) (NN cancer)))) |ET| |BS|4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 15:F01.829.316.616 80:G05.695 556:C11.768.175|ES| 2:1 17:1 18:1 19:1 31:1 131:1 236:1 244:1 403:1 671:1 997:1 2869:1 3577:1
-1 	|BT| (S (PP (IN In) (NP (NN view) (JJ strong) (NN association) (NN estrogen))) (, ,) (NP (NP (NN progesterone)) (, ,) (NP (NN prolactin)) (, ,) (NP (NN breast) (NN cancer)) (, ,) (NP (NN PhIP) (NN repertoire)) (NP (JJ hormone-like) (NN activity))) (VP (VBZ provides) (NP (JJ mechanistic) (NN support) (JJ tissue-specific) (NN carcinogenicity) (NN chemical)))) |ET| |BS|98:A10 161:D06.472 279:D27.888.569.100 386:F02.463.425.069 889:D27.505.696.399.472.277 1010:D04.808.745.745.654.829 1023:D06.472.699.322.576.773|ES| 2:1 18:1 19:1 23:1 244:1 399:1 815:1 1298:1 1364:1 1626:1 1890:1 2124:1 2641:1 3168:1 3536:1 3578:1 3579:1 3580:1 3581:1 3582:1 3583:1
-1 	|BT| (S (ADVP (FW In) (FW vivo)) (, ,) (NP (NP (NP (NN nimbolide)) (PRN (-LRB- -LRB-) (NP (CD 5) (CD 20) (NN mg/kg) (NN body) (NN weight)) (-RRB- -RRB-))) (, ,) (VP (VBN injected) (ADVP (RB intraperitoneally)) (NP (NN tumor) (NN inoculation))) (, ,)) (ADVP (RB significantly)) (VP (VBD decreased) (NP (NN volume) (JJ colorectal) (NN cancer) (NN xenograft)))) |ET| |BS|4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 92:E04.936.764 93:A01.941.875 653:C23.888.144 1024:D20.215.894.200 1025:Z01.252.100.450 1026:Z01.252.474.651|ES| 2:1 7:1 10:1 14:1 17:1 18:1 19:1 124:1 202:1 244:1 265:1 378:1 578:1 1870:1 2398:1 2399:1 3584:1 3585:1 3586:1 3587:1 3588:1 3589:1
-1 	|BT| (S (NP (VBN Increased) (NN expression) (NN cyclooxygenase-2) (NN protein) (NN rat) (NN hepatocarcinogenesis)) (VP (VBD caused) (ADJP (ADJP (JJ choline-deficient)) (, ,) (NP (NP (NN L-amino) (JJ acid-defined) (NN diet) (JJ chemopreventive) (NN efficacy) (JJ specific) (NN inhibitor)) (, ,) (NP (NN nimesulide)))))) |ET| |BS|7:D12.776 24:D08.811.600.720.750 245:B01.050.150.900.649.865.635.505.700 246:B01.050.150.900.649.865.635.505.700 594:D02.033.100.291.211 595:G07.203.650.240 596:E02.642.249 597:D12.125|ES| 2:1 4:1 19:1 61:1 115:1 380:1 540:1 849:1 900:1 1212:1 1946:1 2188:1 2190:1 2191:1 2304:1 2506:1 3183:1 3186:1
-1 	|BT| (NP (NP (NN Inhibition) (NN licorice) (NN flavonoid) (NN oil) (NN glutathione) (JJ S-transferase-positive) (NN focus) (JJ medium-term) (NN rat) (NN hepatocarcinogenesis) (NN bioassay))) |ET| |BS|43:F01.145.544 106:E05.091 245:B01.050.150.900.649.865.635.505.700 246:B01.050.150.900.649.865.635.505.700 534:D03.383.663.283.266.450 780:D08.811.913.225.500 849:G08.686.785.760.769.490.500 914:L01.178 1027:B01.650.940.800.575.100.401.300 1028:B01.650.940.800.575.100.401.300 1029:D10.627.700 1030:D10.627|ES| 19:1 849:1 900:1 1431:1 1886:1 2614:1 2703:1 2744:1 2931:1 3215:1 3590:1 3591:1
-1 	|BT| (S (NP (NN Inhibition) (NN autophagy)) (VP (VBZ potentiates) (NP (JJ antitumor) (NN effect) (NN multikinase) (NN inhibitor) (NN sorafenib) (JJ hepatocellular) (NN carcinoma)))) |ET| |BS|43:F01.145.544 104:C04.557.470.200.025.255 390:G04.299.139.399|ES| 19:1 75:1 303:1 304:1 380:1 1317:1 2063:1 2244:1 2499:1 2703:1 3592:1
-1 	|BT| (NP (NP (NN Inhibition) (JJ hypoxia-inducible) (NN factor) (NN limit) (NN tumor) (NN progression) (NN mouse) (NN model) (JJ colorectal) (NN cancer))) |ET| |BS|4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 8:C04 11:B01.050.150.900.649.865.635.505.500 16:C23.550.291.656 43:F01.145.544 1011:C23.888.852.079 1031:C04.588.274.476.411.307|ES| 7:1 17:1 18:1 19:1 48:1 52:1 72:1 185:1 2703:1 2797:1 3593:1
-1 	|BT| (S (NP (NN Inhibition) (NN STAT3) (NN signaling) (NN pathway) (NN nitidine) (NN chloride)) (VP (VBD suppressed) (NP (NN angiogenesis) (NN growth) (JJ human) (JJ gastric) (NN cancer)))) |ET| |BS|43:F01.145.544 45:G07.700.320.249 55:B01.050.150.900.649.801.400.112.400.400 69:G02.111.087.800 82:D12.644.360.024.342.300 126:G02.111.087.800|ES| 18:1 19:1 36:1 86:1 102:1 195:1 251:1 307:1 383:1 2502:1 2703:1 2788:1 3594:1
-1 	|BT| (S (NP (NP (NN injection) (NN N-diethylnitrosamine)) (PRN (-LRB- -LRB-) (NP (NN DEN)) (-RRB- -RRB-))) (VP (VBP initiate) (NP (NN hepatocarcinogenesis)))) |ET| |BS|30:Z01.058.290.190.800 31:D08.811.520.224.800 226:E02.319.267.530 554:D02.654.442.200|ES| 10:1 14:1 19:1 785:1 900:1 1875:1 3231:1 3595:1
-1 	|BT| (FRAG (UCP (NP (JJ Insulin-independent) (NN promotion)) (ADVP (RB chemically)) (NP (VBN induced) (JJ hepatocellular) (NN tumor) (NN development)) (NP (ADJP (RB genetically) (JJ diabetic)) (NN mouse)))) |ET| |BS|8:C04 11:B01.050.150.900.649.865.635.505.500 637:D06.472.699.587.200.500.625|ES| 7:1 19:1 35:1 52:1 303:1 412:1 898:1 2337:1 2581:1 2964:1 3596:1
-1 	|BT| (NP (NP (NP (NN Intake) (NNS isoflavones)) (SBAR (S (NP (VBN derived) (NN soybean) (NN product)) (VP (MD may) (VP (VB impact) (NP (NN prostate) (NN cancer) (NN risk)))))))) |ET| |BS|61:E05.318.740.600.800 1001:B01.650.940.800.575.100.401.750 1032:D03.383.663.283.266.450.400|ES| 18:1 19:1 77:1 171:1 491:1 675:1 1721:1 3541:1 3597:1 3598:1 3599:1
-1 	|BT| (NP (NP (NP (JJ Interferon-gamma-mediated) (NN hepatocarcinogenesis) (NN mouse)) (VP (VBN treated) (NP (NN diethylnitrosamine))))) |ET| |BS|11:B01.050.150.900.649.865.635.505.500 52:E02 554:D02.654.442.200 1033:D12.644.276.374.440.893|ES| 19:1 52:1 900:1 1099:1 1952:1 3600:1
-1 	|BT| (NP (NP (NN INTERPRETATION)) (: :) (S (S (NP (NN Stimulation) (NN survivin) (NN expression) (NN TCF/beta) (NN catenin)) (VP (MD might) (VP (VB impose) (NP (NN stem) (JJ cell-like) (NN phenotype)) (SBAR (S (NP (JJ colonic) (NN crypt) (NN epithelium) (NN coupling)) (VP (VBD enhanced) (NP (NN cell) (NN proliferation) (NN resistance) (NN apoptosis)))))))) (, ,) (VP (VBP contribute) (NP (JJ molecular) (NN pathogenesis) (JJ colorectal) (NN cancer))))) |ET| |BS|4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 23:D12.776.091.249 39:G04.299.139.160 46:A03.556.124.526.356 62:A10.272 80:G05.695 183:G04.299.233.750 308:A11.872|ES| 2:1 17:1 18:1 19:1 89:1 94:1 104:1 115:1 161:1 173:1 236:1 299:1 385:1 450:1 501:1 677:1 798:1 1094:1 1106:1 2229:1 2913:1 3601:1 3602:1 3603:1 3604:1 3605:1 3606:1 3607:1
-1 	|BT| (NP (NP (NN INTRODUCTION)) (: :) (S (NP (NN Protein) (NN tyrosine) (NN kinase)) (NP (CD 6) (-LRB- -LRB-) (NN PTK6) (-RRB- -RRB-) (JJ non-receptor) (NN tyrosine) (NN kinase)) (ADVP (RB highly)) (VBD expressed) (NP (NP (JJ Human) (NNP Epidermal) (NN Growth) (NN Factor) (CD 2)) (PRN (-LRB- -LRB-) (CC +) (-RRB- -RRB-))) (-LRB- -LRB-) (NP (NP (NN Her2) (PRN (-LRB- -LRB-) (CC +) (-RRB- -RRB-) (-RRB- -RRB-)) (NN breast) (NN cancer))))) |ET| |BS|55:B01.050.150.900.649.801.400.112.400.400 63:G05.360.340.024.340.375.500.791.295.305 65:D08.811.913.696.620.682.725.400.009.400 923:D06.472.317.350 987:D08.811.913.696.620.682.725.400|ES| 6:1 10:1 14:1 18:1 19:1 23:1 104:1 148:1 444:1 470:1 535:1 626:1 1041:1 1044:1 1219:1 2340:1 2341:1 2911:1 3059:1 3529:1 3608:1 3609:1
-1 	|BT| (S (NP (NP (NNP Ling) (NN extract)) (, ,) (NP (JJ high) (NN furanodiene) (NN content)) (, ,)) (VP (VBD showed) (NP (JJ anti-cancer) (NN effect) (NN breast) (NN cancer) (NN cell) (NN vitro)))) |ET| |BS|41:A11|ES| 2:1 18:1 19:1 23:1 75:1 94:1 132:1 178:1 216:1 1112:1 1794:1 2496:1 3610:1 3611:1
-1 	|BT| (S (NP (NN Loss) (NN caspase-8)) (VP (VBZ protects) (SBAR (S (NP (NN mouse) (JJ inflammation-related) (NN hepatocarcinogenesis)) (VP (VBZ induces) (NP (JJ non-apoptotic) (NN liver) (NN injury))))))) |ET| |BS|11:B01.050.150.900.649.865.635.505.500 39:G04.299.139.160 242:A03.620 525:C23.550.470 1034:D08.811.277.656.262.500.126.550.800|ES| 19:1 52:1 214:1 836:1 900:1 1788:1 1863:1 2416:1 3612:1 3613:1 3614:1
-1 	|BT| (S (NP (NN Loss) (NN metallothionein)) (VP (VBZ predisposes) (NP (NN mouse) (JJ diethylnitrosamine-induced) (NN hepatocarcinogenesis) (VBG activating) (NN NF-kappaB) (NN target) (NN gene)))) |ET| |BS|6:G05.360.340.024.340 11:B01.050.150.900.649.865.635.505.500 210:D12.776.260.600 554:D02.654.442.200 777:D12.776.556.670|ES| 9:1 19:1 52:1 160:1 714:1 900:1 1788:1 1948:1 1958:1 2731:1 2732:1
-1 	|BT| (S (S (NP (JJ Low) (NN level) (NN Caspase-3)) (VP (VBP predict) (SBAR (S (NP (JJ favourable) (NN response) (JJ 5FU-based) (NN chemotherapy)) (VP (VBD advanced) (NP (JJ colorectal) (NN cancer))))))) (: :) (S (NP (NN Caspase-3) (NN inhibition) (JJ therapeutic) (NN approach)))) |ET| |BS|4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 43:F01.145.544 52:E02 151:E02.319 333:D01.045 560:D03.383.742.698.875.404 906:D08.811.277.656.262.500.126.350.300|ES| 17:1 18:1 19:1 103:1 104:1 249:1 494:1 495:1 541:1 911:1 997:1 1302:1 2232:1 3190:1 3615:1 3616:1
-1 	|BT| (NP (NP (NNP Lupeol) (NN target) (NN liver) (JJ tumor-initiating) (NN cell) (NN phosphatase) (NN tensin) (NN homolog) (NN modulation))) |ET| |BS|242:A03.620 1035:D08.811.277.352.650 1036:A11.872.650|ES| 19:1 94:1 160:1 836:1 1945:1 3617:1 3618:1 3619:1 3620:1 3621:1
-1 	|BT| (S (S (NP (NNP Lycopene)) (VP (VBZ modulates) (SBAR (S (NP (NN initiation) (NN N-nitrosodiethylamine)) (VP (VBD induced) (NP (NN hepatocarcinogenesis))))))) (: :) (S (NP (NP (NN study) (JJ chromosomal) (NN abnormality)) (, ,) (NP (NN membrane) (NN fluidity) (JJ antioxidant) (NN defense) (NN system))))) |ET| |BS|554:D02.654.442.200 700:D27.505.519.217 1037:C23.550.210 1038:G01.154.500 1039:C16.131.260|ES| 2:1 19:1 104:1 131:1 412:1 593:1 606:1 637:1 900:1 1002:1 1027:1 1104:1 2521:1 2602:1 2733:1 3622:1 3623:1
-1 	|BT| (NP (NP (NNS METHODS) (: :)) (S (NP (DT A) (JJ Solt-Farber) (JJ two-step) (NN test) (NN model) (NN hepatocarcino) (NN genesis)) (VP (VBD established) (S (NP (NP (NP (NP (NP (NN diethylnitrosamine)) (PRN (-LRB- -LRB-) (NP (NN DEN)) (-RRB- -RRB-))) (NN 2-acetylaminofluorene)) (PRN (-LRB- -LRB-) (NP (NN AAF)) (-RRB- -RRB-))) (NN rat)) (VP (VBP investigate) (S (VP (VBG modifying) (NP (NP (NP (NN effect) (NN expression) (NN 6-glucosephosphatase)) (PRN (-LRB- -LRB-) (NP (NN G-6-Pase)) (-RRB- -RRB-))) (, ,) (NP (NN succinodehydrogenase) (-LRB- -LRB-) (NN SDH) (-RRB- -RRB-)) (, ,) (NP (NP (NP (NN adenosine) (NN triphosphatase)) (PRN (-LRB- -LRB-) (NP (NN ATPase)) (-RRB- -RRB-))) (JJ N-nitrosodiethylamine-mediated) (NN hepatocarcinogenesis)))))))))) |ET| |BS|30:Z01.058.290.190.800 31:D08.811.520.224.800 168:E05.581 245:B01.050.150.900.649.865.635.505.700 246:B01.050.150.900.649.865.635.505.700 506:F01.829.263.315 554:D02.654.442.200 767:D02.065.064.150 893:D08.811.277.040.025 894:D08.811.277.040.025 1040:D08.811.277.352.650.225 1041:E01.370.370.380.250|ES| 2:1 10:1 14:1 19:1 69:1 72:1 75:1 104:1 115:1 459:1 565:1 849:1 900:1 1418:1 1875:1 1952:1 2660:1 2762:1 3158:1 3221:1 3271:1 3624:1 3625:1 3626:1 3627:1 3628:1 3629:1 3630:1 3631:1 3632:1 3633:1 3634:1
-1 	|BT| (NP (NP (NNS METHODS) (: :)) (S (NP (JJ Male) (ADJP (ADJP (NN C57BL/6) (NN mouse) (NN fed) (NN methionine) (JJ choline-deficient)) (PRN (-LRB- -LRB-) (NP (NN MCD)) (-RRB- -RRB-))) (NN diet)) (VP (VBP induce) (NP (NN steatohepatitis))))) |ET| |BS|30:Z01.058.290.190.800 31:D08.811.520.224.800 168:E05.581 508:C06.552.241 593:B01.050.050.199.520.520.420 594:D02.033.100.291.211 595:G07.203.650.240 596:E02.642.249 663:C16.320.565.398.500.330.500 664:D02.886.030.676|ES| 10:1 14:1 19:1 52:1 104:1 243:1 565:1 1791:1 2050:1 2188:1 2191:1 2192:1 2426:1 2524:1 3635:1
-1 	|BT| (S (NP (NNP Methylenetetrahydrofolate) (NN reductase) (NN gene) (NN polymorphism) (NN response) (JJ fluorouracil-based) (NN treatment)) (VP (VBD advanced) (NP (JJ colorectal) (NN cancer) (NN patient)))) |ET| |BS|4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 6:G05.360.340.024.340 50:M01.643 52:E02 307:G05.365.795 333:D01.045 560:D03.383.742.698.875.404 606:D08.811.682.662.290|ES| 9:1 17:1 18:1 19:1 96:1 120:1 494:1 546:1 997:1 1060:1 3636:1 3637:1
-1 	|BT| (NP (NP (S (NP (NP (NNS Mice)) (VP (VBG lacking) (NP (NP (NN methionine) (NN adenosyltransferase) (NN 1A)) (PRN (-LRB- -LRB-) (NP (NN MAT1A)) (-RRB- -RRB-))))) (VP (VBD reduced) (NP (NN PHB1) (NN expression)))) (, ,) (JJ impaired) (JJ mitochondrial) (NN function)) (, ,) (VP (ADVP (RB spontaneously)) (VB develop) (NP (NP (JJ hepatocellular) (NN carcinoma)) (PRN (-LRB- -LRB-) (NP (NN HCC)) (-RRB- -RRB-))))) |ET| |BS|11:B01.050.150.900.649.865.635.505.500 104:C04.557.470.200.025.255 565:A11.284.430.214.190.875.564 567:G05.360.340.024.340.365 574:D08.811.913.225.650|ES| 2:1 10:1 14:1 19:1 33:1 115:1 303:1 304:1 376:1 441:1 452:1 583:1 648:1 1506:1 1792:1 2003:1 2004:1 2050:1 2051:1 2052:1 2053:1
-1 	|BT| (S (VP (VBG Modifying) (NP (NP (NN effect) (NN chitin) (, ,) (NN chitosan) (JJ related) (NN compound) (JJ 2-amino-3,8-dimethylimidazo)) (PRN (-LRB- -LSB-) (NP (NP (NP (NP (JJ 4,5-f) (-RRB- -RSB-) (NN quinoxaline)) (PRN (-LRB- -LRB-) (NP (NN MeIQx)) (-RRB- -RRB-))) (NN rat) (JJ medium-term) (NN hepatocarcinogenesis) (NN model)) (, ,) (NP (JJ post-initiation) (NN effect) (JJ female) (NN rat) (JJ 2-stage) (JJ multi-organ) (NN carcinogenesis) (NN model))))))) |ET| |BS|33:C04.697.098 118:D01.248.497.158.380 245:B01.050.150.900.649.865.635.505.700 246:B01.050.150.900.649.865.635.505.700 642:M01.975 849:G08.686.785.760.769.490.500 854:D05.750.078.139.500 855:D05.750.078.139 914:L01.178|ES| 2:1 10:1 14:1 19:1 72:1 75:1 207:1 419:1 849:1 900:1 1373:1 1378:1 1404:1 2433:1 3051:1 3052:1 3215:1 3638:1 3639:1 3640:1 3641:1 3642:1 3643:1 3644:1 3645:1
-1 	|BT| (S (VP (VBG Modifying) (NP (NP (NN effect) (NN liver) (NN tumor) (NN promotion) (NN rat)) (VBN subjected) (NN co-administration) (NN indole-3-carbinol) (NN phenobarbital)))) |ET| |BS|245:B01.050.150.900.649.865.635.505.700 246:B01.050.150.900.649.865.635.505.700 515:C04.588.274.623 756:D03.383.742.698.253.650 1042:Z01.107.757.284|ES| 7:1 19:1 75:1 836:1 849:1 2337:1 2685:1 3267:1 3638:1 3646:1 3647:1
-1 	|BT| (S (NP (NN Monensin)) (VP (VBZ inhibits) (SBAR (S (NP (JJ canonical) (NP (NN Wnt) (NN signaling) (JJ human) (JJ colorectal) (NN cancer) (NN cell))) (VP (VBZ suppresses) (NP (NN tumor) (NN growth) (JJ multiple) (JJ intestinal) (NN neoplasia) (NN mouse))))))) |ET| |BS|4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 8:C04 11:B01.050.150.900.649.865.635.505.500 45:G07.700.320.249 55:B01.050.150.900.649.801.400.112.400.400 69:G02.111.087.800 102:C04.588.274.476.411 122:C14.280.383 1043:D03.383.312.600|ES| 7:1 17:1 18:1 19:1 36:1 52:1 94:1 102:1 109:1 195:1 615:1 640:1 649:1 686:1 877:1 3236:1 3648:1
-1 	|BT| (NP (NP (JJ Mycophenolic) (JJ acid-induced) (NN replication) (NN arrest)) (, ,) (NP (NN differentiation) (NN marker) (NN cell) (NN death) (JJ androgen-independent) (NN prostate) (NN cancer) (NN cell) (NN DU145))) |ET| |BS|41:A11 78:G02.111.087.222 134:G04.299.139 852:C04.588.945.440.770.500 1044:D02.241.081.193.678 1045:D23.050.301.264|ES| 2:1 18:1 19:1 77:1 94:1 215:1 231:1 411:1 534:1 602:1 2599:1 3423:1 3520:1 3649:1
-1 	|BT| (S (NP (NNP Nestin) (NN silencing)) (VP (ADVP (RB also)) (VP (VBD upregulated) (NP (NP (NN Axin) (, ,) (NP (NP (NN glycogen) (NN synthase) (NN kinase-3) (NN beta)) (PRN (-LRB- -LRB-) (NP (NN GSK-3beta)) (-RRB- -RRB-))) (, ,) (NP (JJ adenomatous) (NN polyposis) (NN coli) (PRN (-LRB- -LRB-) (NP (NN APC)) (-RRB- -RRB-))) (, ,)) (NP (NP (NN peroxisome) (JJ proliferator-activated) (NN receptor) (NN alpha)) (PRN (-LRB- -LRB-) (NP (NN PPARa)) (-RRB- -RRB-))))) (, ,) (VP (VBD downregulated) (NP (NP (NN beta-catenin)) (, ,) (NP (NN c-Myc)) (, ,) (NP (NP (NN cyclin) (NN D)) (NN MMP-7) (NN expression) (NNP CSC)))))) |ET| |BS|3:C04.557.470.035.215.100 21:G05.360.340.024.340.375.249.050 23:D12.776.091.249 536:D12.776.826.239.500 556:C11.768.175 937:D08.811.277.656.300.480.525.700.250 1046:D12.644.360.262.150 1047:D05.750.078.593.540|ES| 2:1 5:1 10:1 11:1 14:1 19:1 57:1 58:1 59:1 60:1 66:1 92:1 100:1 115:1 125:1 186:1 426:1 743:1 824:1 1801:1 1836:1 1887:1 1972:1 2592:1 3577:1 3650:1 3651:1 3652:1 3653:1 3654:1 3655:1
-1 	|BT| (NP (NP (NP (NP (NNP Neurotensin) (NN receptor-1)) (PRN (-LRB- -LRB-) (NP (NN NTR-1)) (-RRB- -RRB-))) (NP (JJ overexpressed) (NN colon) (NN cancer) (NN colon) (NN cancer) (NN cell) (NN line)))) |ET| |BS|94:A11.251.210 1048:D12.776.543.750.100.550|ES| 10:1 14:1 18:1 19:1 25:1 94:1 113:1 264:1 3656:1 3657:1 3658:1
-1 	|BT| (S (NP (NN Nifuroxazide)) (VP (VBZ induces) (SBAR (S (NP (NN apoptosis)) (VP (VBZ impairs) (NP (JJ pulmonary) (NN metastasis) (NN breast) (NN cancer) (NN model))))))) |ET| |BS|10:A01.236 39:G04.299.139.160 113:C04.697.650 182:A04.411|ES| 18:1 19:1 23:1 72:1 89:1 214:1 806:1 948:1 2729:1 3659:1
-1 	|BT| (NP (NP (NP (JJ Nitric) (JJ oxide-releasing) (NN aspirin) (NN indomethacin) (JJ potent) (NN inhibitor) (NN colon) (NN cancer) (JJ azoxymethane-treated) (NN rat)) (: :) (NP (NN effect) (JJ molecular) (NN target)))) |ET| |BS|52:E02 132:D02.172.080 245:B01.050.150.900.649.865.635.505.700 246:B01.050.150.900.649.865.635.505.700 795:D03.438.473.420|ES| 18:1 19:1 22:1 75:1 104:1 113:1 160:1 161:1 380:1 849:1 2487:1 2790:1 2791:1 2792:1 2793:1
-1 	|BT| (NP (NP (DT No) (VBG Modifying) (NP (NP (NN Effect) (JJ Antioxidant) (NN N-Acetyl-L-Cysteine)) (JJ Fenofibrate-induced) (NNP Hepatocarcinogenesis) (NNS Rats)))) |ET| |BS|13:D01.339.387 245:B01.050.150.900.649.865.635.505.700 246:B01.050.150.900.649.865.635.505.700 791:D02.886.030.230.259 916:D02.241.081.114.968.500.625 1049:D27.505.519.217|ES| 19:1 1959:1 3222:1 3638:1 3660:1 3661:1 3662:1 3663:1 3664:1
-1 	|BT| (S (NP (JJ Nuclear) (NN Maspin) (NN expression)) (NP (ADJP (RB highly) (JJ predictive)) (NN 5-FU) (NN chemotherapy) (NN response) (NN patient)) (VP (VBD advanced) (NP (NN stage) (NN colon) (NN cancer)))) |ET| |BS|50:M01.643 151:E02.319 560:D03.383.742.698.875.404|ES| 18:1 19:1 113:1 115:1 120:1 494:1 495:1 533:1 626:1 997:1 1129:1 2308:1 2808:1 2809:1
-1 	|BT| (S (NP (NN OBJECTIVE) (: :)) (NP (NP (NN Vitamin) (NN D)) (PRN (-LRB- -LRB-) (NP (CD 3)) (-RRB- -RRB-))) (VP (VBN upregulated) (NP (NP (NN protein) (CD 1) (PRN (-LRB- -LRB-) (NP (NN VDUP1)) (-RRB- -RRB-))) (NP (NP (JJ potent) (NN tumour) (NN suppressor)) (SBAR (WHNP (WP$ whose) (NN expression)) (S (ADVP (RB dramatically)) (VP (VBD reduced) (NP (NP (JJ various) (NN type) (JJ human) (NN cancer)) (, ,) (PP (VBG including) (NP (JJ gastric) (NN cancer))))))))))) |ET| |BS|55:B01.050.150.900.649.801.400.112.400.400 206:G05.360.340.024.340.375.249 415:F01.658.500 1050:D12.776.157.125.050.060 1051:D04.808.247.222.159 1052:D12.776.641.750|ES| 2:1 4:1 10:1 14:1 18:1 19:1 22:1 36:1 86:1 98:1 104:1 115:1 125:1 452:1 543:1 561:1 645:1 700:1 862:1 919:1 1011:1 1096:1 1417:1 2592:1 3665:1 3666:1
-1 	|BT| (NP (NP (JJ Oncogenic) (NN tumor) (JJ suppressive) (NN role)) (NP (JJ polo-like) (NN kinase) (JJ human) (JJ hepatocellular) (NN carcinoma))) |ET| |BS|8:C04 15:F01.829.316.616 55:B01.050.150.900.649.801.400.112.400.400 104:C04.557.470.200.025.255 279:D27.888.569.100|ES| 7:1 19:1 31:1 36:1 303:1 304:1 470:1 1974:1 2143:1 3667:1
-1 	|BT| (NP (NP (CD One) (JJ reasonable) (NN possibility) (JJ attributable) (NN hyperinsulinemia) (JJ compensatory) (JJ obesity-related) (NN insulin) (NN resistance))) |ET| |BS|564:C18.654.726.500 678:C18.452.394.968.500 1053:C18.452.394.968|ES| 19:1 343:1 654:1 1094:1 2364:1 2467:1 3668:1 3669:1 3670:1 3671:1
-1 	|BT| (S (NP (PRP$ Our) (NN observation)) (VP (VBP suggest) (NP (NP (JJ chemoprotective) (NN effect) (NN isorhamnetin) (NN colon) (NN cancer)) (VP (VBN linked) (NP (NP (JJ anti-inflammatory) (NN activity) (NN inhibition) (JJ oncogenic) (NN Src) (NN activity) (JJ consequential) (NN loss)) (VP (JJ nuclear) (NP (NP (NN beta-catenin)) (, ,) (NP (NN activity)) (NP (JJ dependent) (NN CSK) (NN expression))))))))) |ET| |BS|23:D12.776.091.249 43:F01.145.544 279:D27.888.569.100 429:N04.761.559.590.900 430:E05.581.249 686:D27.505.954.158|ES| 2:1 18:1 19:1 32:1 60:1 75:1 103:1 113:1 115:1 321:1 399:1 658:1 796:1 953:1 1256:1 1363:1 1477:1 2795:1 3672:1 3673:1 3674:1 3675:1 3676:1
-1 	|BT| (S (VP (PRP$ Our) (S (VP (VBP result) (VP (VBP demonstrate) (S (NP (JJ potential) (JJ therapeutic) (NN role) (NN panobinostat)) (VP (VBG targeting) (NP (JJ aggressive) (JJ triple-negative) (NN breast) (NN cancer) (NN cell) (NN type))))))))) |ET| |BS|15:F01.829.316.616 41:A11 52:E02 160:C04.588.180.788 162:F01.145.126.125|ES| 18:1 19:1 23:1 26:1 31:1 94:1 101:1 502:1 538:1 541:1 543:1 616:1 658:1 827:1 3348:1
-1 	|BT| (NP (NP (PRP$ Our) (VP (VBP result) (VP (VBP demonstrate) (S (VP (NN resveratrol) (VP (VB potentiate) (NP (JJ anti-tumor) (NN effect) (NN 5-FU) (NN CRC) (NN cell) (NN chemosensitizing)) (, ,) (S (VP (VBG inhibiting) (NP (NNP EMT) (NN phenotype)) (PP (IN via) (NP (NN up-regulation) (JJ intercellular) (NN junction) (NN down-regulation) (NN NF-kappaB) (NN pathway)))))))))))) |ET| |BS|4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 8:C04 12:Z01.542.049 41:A11 80:G05.695 85:G02.111.087.225 122:C14.280.383 142:I01.880.604 210:D12.776.260.600 560:D03.383.742.698.875.404 1054:A11.284.149.165.420|ES| 2:1 19:1 75:1 94:1 101:1 236:1 245:1 257:1 383:1 502:1 596:1 658:1 714:1 880:1 896:1 1712:1 1759:1 2075:1 2308:1 3677:1 3678:1 3679:1 3680:1
-1 	|BT| (FRAG (ADVP (RB Overall)) (, ,) (NP (NP (JJ 2-SeCD) (NNS sensitises) (JJ resistant) (NN breast) (NN cancer) (NN cell) (JJ TRAIL-based) (NN apoptosis)) (ADVP (FW vitro) (FW vivo)))) |ET| |BS|39:G04.299.139.160 41:A11 333:D01.045 696:V02.270.500|ES| 2:1 18:1 19:1 23:1 89:1 94:1 216:1 378:1 427:1 2858:1 3681:1 3682:1 3683:1
-1 	|BT| (NP (NP (NN Overexpression) (NN 5-lipoxygenase) (NN colon) (NN polyp) (NN cancer) (NN effect) (NN 5-LOX) (NN inhibitor) (NN vitro) (JJ murine) (NN model))) |ET| |BS|11:B01.050.150.900.649.865.635.505.500 548:D08.811.682.664.500.848 1055:D08.811.682.690.416.583.625 1056:C23.300.825.411.235|ES| 18:1 19:1 72:1 75:1 113:1 216:1 380:1 627:1 647:1 668:1 3390:1 3684:1
-1 	|BT| (S (NP (NP (NN Overexpression) (NN cyclooxygenase) (CD 2)) (PRN (-LRB- -LRB-) (NP (NN COX2)) (-RRB- -RRB-))) (NP (NP (JJ uncontrolled) (JJ wingless) (NN Int) (-LRB- -LRB-) (NN Wnt) (-RRB- -RRB-) (: -)) (NN signaling) (NN pathway)) (ADVP (RB long)) (VP (VBD suggested) (NP (NP (NN play) (JJ crucial) (NN role)) (NP (JJ colorectal) (NN cancer))))) |ET| |BS|4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 15:F01.829.316.616 24:D08.811.600.720.750 30:Z01.058.290.190.800 31:D08.811.520.224.800 79:I03.450.642.693 147:G02.149.115.800.925|ES| 10:1 14:1 17:1 18:1 19:1 31:1 148:1 238:1 383:1 668:1 877:1 925:1 2325:1 3180:1 3685:1 3686:1 3687:1 3688:1 3689:1 3690:1
-1 	|BT| (S (NP (NP (NN Overexpression) (NN cyclooxygenase) (CD 2)) (PRN (-LRB- -LRB-) (NP (NN COX-2)) (-RRB- -RRB-))) (ADVP (RB frequently)) (VP (VBD found) (NP (JJ early) (JJ advanced) (NN lung) (NN cancer)))) |ET| |BS|24:D08.811.600.720.750|ES| 10:1 14:1 18:1 19:1 37:1 76:1 148:1 328:1 668:1 698:1 997:1 1128:1 3180:1
-1 	|BT| (S (NP (NN Overexpression) (NN glutamine) (NN synthetase)) (VP (VBN associated) (NP (NNS beta-catenin-mutations) (NN mouse) (NN liver) (NN tumor) (NN promotion) (NN hepatocarcinogenesis) (NN phenobarbital)))) |ET| |BS|11:B01.050.150.900.649.865.635.505.500 18:G05.365.590 23:D12.776.091.249 515:C04.588.274.623 756:D03.383.742.698.253.650 1057:D08.811.464.259.200.600|ES| 7:1 19:1 52:1 169:1 668:1 836:1 900:1 2337:1 2685:1 3691:1 3692:1 3693:1
-1 	|BT| (S (NP (NN Pamidronate)) (VP (VBD induced) (NP (JJ anti-proliferative) (, ,) (NP (JJ apoptotic) (, ,) (NP (JJ anti-migratory) (NN effect) (JJ hepatocellular) (NN carcinoma)))))) |ET| |BS|39:G04.299.139.160 104:C04.557.470.200.025.255|ES| 2:1 19:1 75:1 303:1 304:1 412:1 2223:1 3694:1 3695:1 3696:1
-1 	|BT| (S (NP (JJ Past) (NN study)) (VP (VBN shown) (VP (VBD amplified) (NP (NP (NP (JJ insulin-like) (NN growth) (NN factor) (CD 1)) (PRN (-LRB- -LRB-) (NP (NN IGF1)) (-RRB- -RRB-))) (: /) (NP (NP (NP (NP (NN IGF1) (NN receptor)) (PRN (-LRB- -LRB-) (NP (NN IGF1-R)) (-RRB- -RRB-))) (NN signalling) (JJ important) (NN role)) (NP (NP (NP (JJ colorectal) (NN cancer)) (PRN (-LRB- -LRB-) (NP (NN CRC)) (-RRB- -RRB-))) (NP (NN development)))) (, ,) (NP (NN progression) (NN resistance) (NN treatment)))))) |ET| |BS|4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 12:Z01.542.049 15:F01.829.316.616 16:C23.550.291.656 52:E02 518:D08.811.913.696.620.682.725.400.185 598:D12.644.276.937.400 599:M01.526.799.500|ES| 2:1 10:1 14:1 17:1 18:1 19:1 31:1 35:1 48:1 98:1 102:1 131:1 185:1 186:1 237:1 245:1 546:1 902:1 1094:1 2093:1 2198:1 2208:1 2437:1 3697:1 3698:1 3699:1
-1 	|BT| (NP (NP (NNS Polymorphisms) (NP (JJ estrogen-metabolizing) (NN gene) (NN risk) (JJ hepatocellular) (NN carcinoma)) (NNP Taiwan) (NN female))) |ET| |BS|6:G05.360.340.024.340 61:E05.318.740.600.800 104:C04.557.470.200.025.255 307:G05.365.795 889:D27.505.696.399.472.277 1058:Z01.252.474.872|ES| 9:1 19:1 171:1 303:1 304:1 1404:1 3700:1 3701:1 3702:1
-1 	|BT| (NP (NP (NNP Prevention) (JJ upper) (JJ aerodigestive) (NN tract) (NN cancer) (JJ zinc-deficient) (JJ rodent)) (: :) (NP (NN inefficacy) (JJ genetic) (JJ pharmacological) (NN disruption) (NN COX-2))) |ET| |BS|514:B01.050.150.900.649.865 874:D01.268.556.940 1059:H01.158.703|ES| 18:1 19:1 76:1 104:1 864:1 1602:1 2173:1 2898:1 3101:1 3703:1 3704:1 3705:1 3706:1 3707:1
-1 	|BT| (S (ADVP (RB Previously)) (, ,) (VP (VBD showed) (SBAR (S (NP (JJ habitual) (JJ heavy) (NN alcohol) (NN ingestion)) (VP (VBD amplified) (S (NP (NP (JJ age-related) (NN hepatocarcinogenesis) (NN P) (NN rat)) (, ,) (NP (NP (CD 80) (NN %)) (NP (JJ alcohol-consuming) (NP (NN P) (NN rat) (VBG developing) (NNS HCCs)) (NP (CD 18) (NN month) (NN alcohol) (NN exposure)))) (, ,)) (VP (VBN compared) (NP (ADJP (CD 5) (NN %)) (NN water-drinking) (NN control))))))))) |ET| |BS|104:C04.557.470.200.025.255 245:B01.050.150.900.649.865.635.505.700 246:B01.050.150.900.649.865.635.505.700 751:D02.033.375 822:D02.033 904:F01.145.317.269 1060:D01.045.250.875.300|ES| 2:1 19:1 50:1 132:1 289:1 311:1 369:1 573:1 578:1 590:1 767:1 849:1 900:1 1132:1 1953:1 2208:1 2723:1 3708:1 3709:1 3710:1 3711:1 3712:1 3713:1 3714:1 3715:1
-1 	|BT| (NP (NP (JJ Prognostic) (NN significance) (NN metallothionein) (JJ human) (JJ gastrointestinal) (NN cancer))) |ET| |BS|55:B01.050.150.900.649.801.400.112.400.400 777:D12.776.556.670|ES| 18:1 19:1 36:1 183:1 557:1 2731:1 3716:1
-1 	|BT| (NP (NP (NNP Promotion) (NN hepatocarcinogenesis) (NN perfluoroalkyl) (NN acid) (NN rainbow) (NNS trout))) |ET| |BS|38:Z01.058.290.120.180 40:Z01.542.248.700 1061:B01.050.150.900.493.817.750.825.580.600 1062:D01.029|ES| 19:1 900:1 1275:1 3717:1 3718:1 3719:1 3720:1
-1 	|BT| (NP (NP (NP (NN Protein) (NN kinase) (NN Cbeta)) (NP (JJ effective) (NN target) (NN chemoprevention) (NN colon) (NN cancer)))) |ET| |BS|12:Z01.542.049 253:E02.319.162 867:D08.811.913.696.620.682.700.725.049|ES| 18:1 19:1 113:1 160:1 470:1 870:1 1639:1 2911:1 3721:1
-1 	|BT| (S (NP (NP (NN Protein) (NN kinase) (NN CbetaII)) (PRN (-LRB- -LRB-) (NP (NN PKCbetaII)) (-RRB- -RRB-))) (VP (VP (VBP play) (NP (JJ requisite) (NN role) (NN initiation) (NN colon)) (NP (NP (NN carcinogenesis) (JJ preclinical) (NN mouse) (NN model)) (VP (VBG promoting) (NP (NN proliferation))))) (VP (VBD increased) (NP (NN beta-catenin) (NN accumulation))))) |ET| |BS|11:B01.050.150.900.649.865.635.505.500 15:F01.829.316.616 23:D12.776.091.249 33:C04.697.098 46:A03.556.124.526.356 79:I03.450.642.693 866:D08.811.913.696.620.682.700.725.049 1063:D08.811.913.696.620.682|ES| 10:1 14:1 19:1 31:1 47:1 52:1 60:1 72:1 113:1 207:1 238:1 299:1 470:1 637:1 881:1 1494:1 2120:1 2911:1 3077:1 3722:1 3723:1
-1 	|BT| (S (NP (NN Protein) (NN kinase) (NN D1)) (VP (VBZ attenuates) (NP (NP (NN tumorigenesis) (NN colon) (NN cancer)) (VP (VBG modulating) (NP (NN beta-catenin/T) (NN cell) (NN factor) (NN activity)))))) |ET| |BS|23:D12.776.091.249 32:C04.697.098.500 33:C04.697.098 68:A11.118.637.555.567.569 1063:D08.811.913.696.620.682|ES| 18:1 19:1 78:1 94:1 113:1 185:1 399:1 470:1 744:1 2423:1 2435:1 2911:1 3724:1
-1 	|BT| (NP (NP (NN PURPOSE) (: :)) (NP (NP (NP (NP (JJ Fatty) (NN acid) (NN synthase)) (PRN (-LRB- -LRB-) (NP (NN FAS)) (-RRB- -RRB-))) (NP (JJ overexpressed) (NN lung) (NN cancer))) (, ,) (VP (VBD investigated) (NP (JJ potential) (NN use) (NN FAS) (NN inhibitor) (NN chemoprevention) (NN lung) (NN cancer))))) |ET| |BS|253:E02.319.162 921:D08.811.682.664.500.772 922:D10.251|ES| 2:1 10:1 14:1 18:1 19:1 25:1 66:1 104:1 328:1 380:1 403:1 687:1 827:1 870:1 1275:1 1659:1 3725:1 3726:1
-1 	|BT| (NP (NP (NP (NP (NN PURPOSE) (: :)) (NN Obesity) (JJ related) (JJ metabolic) (NN abnormality)) (, ,) (PP (VBG including) (NP (NP (NN insulin) (NN resistance)) (VP (NN activation) (NP (NP (NP (JJ insulin-like) (NN growth) (NN factor)) (PRN (-LRB- -LRB-) (NP (NN IGF)) (-RRB- -RRB-))) (: /) (NP (NP (NP (NN IGF-I) (NN receptor)) (PRN (-LRB- -LRB-) (NP (NN IGF-IR)) (-RRB- -RRB-))) (NN axis) (, ,) (NN risk) (NN factor) (NN colon) (NN cancer)))))))) |ET| |BS|254:C16.131 409:E05.318.740.600.800.725 518:D08.811.913.696.620.682.725.400.185 564:C18.654.726.500 579:A02.835.232.834.151.383 581:D12.644.276.937 678:C18.452.394.968.500 1064:Z01.252.245.500.350 1065:D01.268.556.401|ES| 2:1 10:1 14:1 18:1 19:1 102:1 104:1 113:1 171:1 185:1 186:1 225:1 419:1 561:1 687:1 1027:1 1094:1 2006:1 2089:1 2093:1 2364:1 3727:1 3728:1 3729:1 3730:1
-1 	|BT| (S (NP (NP (NN PURPOSE) (: :)) (NP (NP (NP (NN Signal) (NN transducer) (NN activator) (NN transcription-3)) (PRN (-LRB- -LRB-) (NP (NN STAT3)) (-RRB- -RRB-))) (NP (JJ downstream) (NN growth) (NN factor) (NN cytokine) (NN receptor))) (, ,)) (VP (VBZ regulates) (NP (NP (JJ key) (JJ oncogenic) (NN pathway) (JJ non-small) (NN cell) (NN lung) (NN cancer)) (PRN (-LRB- -LRB-) (NP (NN NSCLC)) (-RRB- -RRB-))))) |ET| |BS|82:D12.644.360.024.342.300 110:C04.588.894.797.520.109.220.249 209:G02.111.087.847 250:E07.305.812 279:D27.888.569.100 897:Z01.252.245.500.375 1066:D12.776.543.750.705.852|ES| 2:1 10:1 14:1 18:1 19:1 94:1 102:1 104:1 159:1 185:1 186:1 251:1 328:1 329:1 383:1 560:1 603:1 687:1 694:1 860:1 861:1 953:1 2676:1 2960:1 3731:1
-1 	|BT| (NP (NP (NP (JJ Quantitative) (NN analysis) (JJ basic) (NN fibroblast) (NN growth) (NN factor) (JJ vascular) (JJ endothelial) (NN growth) (NN factor)) (NP (JJ human) (JJ colorectal) (NN cancer)))) |ET| |BS|4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 1067:D12.644.276.624.120|ES| 17:1 18:1 19:1 36:1 102:1 185:1 661:1 1251:1 2213:1 3092:1 3732:1 3733:1
-1 	|BT| (NP (NP (NP (VBN Reduced) (NN expression) (NN cyclooxygenase) (CD 2) (NN protein) (JJ hereditary) (JJ nonpolyposis) (JJ colorectal) (NN cancer)) (JJ relative) (JJ sporadic) (NN cancer))) |ET| |BS|7:D12.776 24:D08.811.600.720.750 524:C04.588.274.476.411.307.190|ES| 4:1 17:1 18:1 19:1 115:1 148:1 725:1 1531:1 1845:1 1846:1 3180:1 3734:1
-1 	|BT| (S (NP (NN Regrowth) (JJ 5-fluorouracil-treated) (JJ human) (NN colon) (NN cancer) (NN cell)) (VP (VBD prevented) (NP (NP (NN combination) (NN interferon) (NN gamma)) (, ,) (NP (NN indomethacin)) (, ,) (NP (NN phenylbutyrate))))) |ET| |BS|41:A11 52:E02 55:B01.050.150.900.649.801.400.112.400.400 560:D03.383.742.698.875.404 795:D03.438.473.420 1033:D12.644.276.374.440.893 1068:D02.241.223.651|ES| 2:1 18:1 19:1 36:1 94:1 113:1 530:1 1944:1 2305:1 2389:1 2792:1 3735:1 3736:1 3737:1
-1 	|BT| (NP (NP (NNS RESULTS) (: :)) (NP (NP (NN 5-LOX) (VBN overexpressed) (JJ adenomatous) (NN polyp) (NN cancer)) (NP (VBN compared) (JJ normal) (JJ colonic) (NN mucosa)))) |ET| |BS|46:A03.556.124.526.356 302:A10.615.550 548:D08.811.682.664.500.848 551:C04.557.470.035.215|ES| 18:1 19:1 25:1 50:1 57:1 104:1 118:1 579:1 647:1 677:1 710:1 3390:1
-1 	|BT| (S (NP (NNS RESULTS)) (: :) (S (NP (NN Microarray) (NN analysis)) (VP (VBD revealed) (SBAR (S (NP (NP (NN osteopontin)) (, ,) (NP (NN marker) (NN colon) (NN cancer) (NN progression)) (, ,)) (VP (VBD down-regulated) (NP (NP (NP (NN polyp) (NN Apc)) (PRN (-LRB- -LRB-) (NP (NN Delta14)) (: /) (CC +) (-RRB- -RRB-))) (NN mouse) (VBN given) (NN parecoxib)) (NP (VBN compared) (NN control)))))))) |ET| |BS|3:C04.557.470.035.215.100 11:B01.050.150.900.649.865.635.505.500 16:C23.550.291.656 142:I01.880.604 158:D23.101 350:D12.644.276.374.625 351:A17.360 444:C23.300.825 718:E05.588.570|ES| 2:1 10:1 14:1 18:1 19:1 29:1 48:1 50:1 52:1 104:1 113:1 275:1 280:1 281:1 289:1 534:1 647:1 661:1 710:1 1160:1 1283:1 3738:1 3739:1
-1 	|BT| (NP (NP (NNS RESULTS) (: :)) (S (NP (NN Nestin) (NN expression)) (ADVP (RB significantly)) (VP (VBD associated) (NP (NP (JJ poor) (NN survival) (NN patient) (JJ triple-negative) (NN breast) (NN cancer)) (PRN (-LRB- -LRB-) (S (NP (NN P)) (VP (JJ =) (NP (CD 0.01)))) (-RRB- -RRB-)))))) |ET| |BS|50:M01.643 96:I03.784 159:I01.880.735.634 160:C04.588.180.788 1047:D05.750.078.593.540|ES| 10:1 14:1 18:1 19:1 23:1 26:1 104:1 115:1 120:1 124:1 169:1 274:1 311:1 315:1 545:1 581:1 710:1 3650:1
-1 	|BT| (S (NP (NN Resveratrol)) (VP (VBZ induces) (NP (NP (NN chemosensitization) (NN 5-fluorouracil) (NN up-regulation) (JJ intercellular) (NN junction)) (, ,) (NP (JJ Epithelial-to-mesenchymal) (NN transition) (NN apoptosis) (JJ colorectal) (NN cancer))))) |ET| |BS|4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 39:G04.299.139.160 142:I01.880.604 495:G04.299.335.500 560:D03.383.742.698.875.404 1054:A11.284.149.165.420|ES| 2:1 17:1 18:1 19:1 89:1 214:1 552:1 896:1 2307:1 2946:1 3679:1 3680:1 3740:1 3741:1
-1 	|BT| (S (S (NP (NP (NN RNA) (NN interference) (JJ knockdown) (NN DRD2) (NN inhibition) (JJ pharmacologic) (NN antagonist)) (PRN (-LRB- -LRB-) (NP (NN pimozide) (NN haloperidol)) (-RRB- -RRB-))) (VP (VBD reduced) (NP (NN proliferation) (JJ pancreatic) (NN cancer) (NN cell)))) (, ,) (VP (VBD induced) (NP (NP (JJ endoplasmic) (NN reticulum) (NN stress) (NN apoptosis)) (, ,) (NP (VBN reduced) (NN cell) (NN migration))))) |ET| |BS|39:G04.299.139.160 43:F01.145.544 156:G05.355.315.203.374.790 183:G04.299.233.750 362:D12.776.543.750.069.300.400.500 681:G04.299.283 1059:H01.158.703 1069:D02.522.352.506 1070:D03.438.103.732 1071:G04.434|ES| 2:1 10:1 14:1 18:1 19:1 89:1 94:1 103:1 299:1 412:1 452:1 464:1 467:1 514:1 515:1 516:1 1210:1 1271:1 2522:1 3742:1 3743:1 3744:1 3745:1 3746:1
-1 	|BT| (S (NP (NN Role) (NN microRNA-155) (JJ early) (NN stage) (NN hepatocarcinogenesis)) (VP (VBD induced) (NP (JJ choline-deficient) (NN amino) (JJ acid-defined) (NN diet) (NN C57BL/6) (NN mouse)))) |ET| |BS|15:F01.829.316.616 184:D13.150.650.319 593:B01.050.050.199.520.520.420 594:D02.033.100.291.211 595:G07.203.650.240 596:E02.642.249 597:D12.125|ES| 19:1 52:1 412:1 900:1 1128:1 1129:1 1957:1 2187:1 2188:1 2189:1 2190:1 2191:1 2192:1
-1 	|BT| (NP (NP (NN Role) (JJ transcriptional) (JJ posttranscriptional) (NN regulation) (NN methionine) (NNS adenosyltransferases) (NN liver) (NN cancer) (NN progression))) |ET| |BS|15:F01.829.316.616 16:C23.550.291.656 142:I01.880.604 209:G02.111.087.847 574:D08.811.913.225.650|ES| 18:1 19:1 48:1 438:1 559:1 836:1 1493:1 2050:1 2187:1 3747:1
-1 	|BT| (S (NP (NN Roxithromycin)) (VP (VBZ inhibits) (S (NP (NP (JJ constitutive) (NN activation) (JJ nuclear) (NN factor)) (-LRB- -LCB-) (NN kappa) (-RRB- -RCB-) (NN B)) (VP (VBG diminishing) (NP (JJ oxidative) (NN stress) (NN rat) (NN model) (JJ hepatocellular) (NN carcinoma)))))) |ET| |BS|38:Z01.058.290.120.180 40:Z01.542.248.700 104:C04.557.470.200.025.255 122:C14.280.383 210:D12.776.260.600 245:B01.050.150.900.649.865.635.505.700 246:B01.050.150.900.649.865.635.505.700 716:G03.495.710 843:D02.540.576.500.992.630|ES| 19:1 72:1 185:1 225:1 303:1 304:1 604:1 615:1 763:1 849:1 1256:1 2522:1 2583:1 3748:1 3749:1 3750:1 3751:1 3752:1
-1 	|BT| (NP (NP (JJ Seleno-cyclodextrin) (NNS sensitises) (JJ human) (NN breast) (NN cancer) (NN cell) (JJ TRAIL-induced) (NN apoptosis) (NN DR5) (NN induction) (NN NF-kappaB) (NN suppression))) |ET| |BS|39:G04.299.139.160 41:A11 55:B01.050.150.900.649.801.400.112.400.400 210:D12.776.260.600 1072:D04.345.103|ES| 18:1 19:1 23:1 36:1 89:1 94:1 714:1 736:1 2453:1 3682:1 3753:1 3754:1 3755:1
-1 	|BT| (S (NP (NN Selenoprotein) (NN deficiency) (JJ high) (NN level) (NN selenium) (NN compound)) (ADVP (RB effectively)) (VP (VBP inhibit) (NP (NN hepatocarcinogenesis) (JJ transgenic) (NN mouse)))) |ET| |BS|87:C18.654.521 99:B01.050.050.136.500 122:C14.280.383 1073:D12.776.864 1074:D01.810|ES| 19:1 52:1 178:1 249:1 253:1 285:1 900:1 1370:1 2433:1 2977:1 3284:1 3756:1
-1 	|BT| (S (NP (NP (NN Signal) (NN transducer) (NN activator) (NN transcription) (CD 3)) (PRN (-LRB- -LRB-) (NP (NN STAT3)) (-RRB- -RRB-))) (VP (VBZ mediates) (NP (NN pathogenesis) (NN colon) (NN cancer) (NN substrate) (NN PTK6)))) |ET| |BS|209:G02.111.087.847 250:E07.305.812|ES| 10:1 14:1 18:1 19:1 113:1 251:1 487:1 501:1 755:1 860:1 861:1 862:1 1041:1 2960:1 3757:1
